Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13,\ 04/03/1$

ARBN				
621 8	66 813			
We (tl	We (the entity) give ASX the following information.			
	t 1 - All issues ust complete the relevant sections (attach sh	neets if there is not enough space).		
1	⁺ Class of ⁺ securities issued or to be issued	1. Shares and Chess Depository Interest (CDIs) representing fully paid ordinary shares (Shares).		

Number of +securities issued or to be issued (if known) or maximum number which may be issued

Name of entity

Credible Labs Inc.

1. 212,050 CDIs (representing 8,482 Shares)

2. Unquoted Options (Options) to purchase

2. 25,000 Options

Shares.

⁺ See chapter 19 for defined terms.

3 Principal terms of the

+securities (e.g. if options,
exercise price and expiry date;
if partly paid +securities, the
amount outstanding and due
dates for payment; if

+convertible securities, the
conversion price and dates for
conversion)

25 CDIs represent 1 Share.

212,050 CDIs (representing 8,482 Shares) issued on exercise of Unquoted Options.

As per the standard form of Notice of Stock Option Grant and Stock Option Agreement previously approved by the Board for use under the Company's Amended and Restated 2012 Stock Plan (the "2012 Plan").

Options are exercisable at USD\$15.99 being the per share exercise price for each Option equal to the closing price of one CHESS Depositary Interest (CDI) on the effective date of approval by the directors, as adjusted as necessary to reflect the CDI/per share of Common Stock ratio in effect as of such effective date (with the effective date of approval by the directors determined based on Australian Standard Time as of the time of approval by the directors and with such per share price adjusted to take into account the exchange rate for such currency as published on wsj.com for such effective date).

The Options expire on 9th September 2028 representing a maximum 10-year term. Options shall vest and be exercisable at the rate of 25% of the total Shares underlying the Option on the 12-month anniversary of the Vesting Commencement Date, and 1/16th of the total shares underlying the Option shall vest and become exercisable on the same day of each month thereafter for so long as the Optionee remains in Continuous Service Status (as defined in the 2012 Plan) or, if there is no such date, the last day of the month.

⁺ See chapter 19 for defined terms.

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration
- 6 Purpose of the issue
 (If issued as consideration for
 the acquisition of assets,
 clearly identify those assets)
- 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the* +*securities the subject of this Appendix 3B*, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- Number of +securities issued without security holder approval under rule 7.1

25 CDIs represent 1 Share.

Options are not quoted on the ASX.

Only CDIs are quoted on the ASX. CDIs issued on exercise of the Options will rank equally with CDIs quoted on the ASX in all respects.

Shares are not quoted on the ASX and do not rank equally with CDIs quoted on the ASX. In accordance with the Company's Prospectus dated 28 November 2017, CDIs represent the beneficial interest in the Shares of the Company.

- 1. 8,482 Unquoted Options (representing 212,050 CDI's) were exercised at an exercise price of USD\$1.25 per Share.
- 2. Nil.
- 1. Issued on exercise of Unquoted Options.
- 2. Issue of Options pursuant to the Company's 2012 Plan

N/A

N/A

N/A

⁺ See chapter 19 for defined terms.

6d	Number of ⁺ securities issued with security holder approval under rule 7.1A	N/A
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of ⁺ securities issued under an exception in rule 7.2	N/A
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A
7	⁺ Issue dates	11 September 2018
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	

⁺ See chapter 19 for defined terms.

Number and +class of all
+securities quoted on ASX
(including the +securities in section 2 if applicable)

Number	+Class
131,563,700	CDIs (representing
	5,262,548 Shares)

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
121,460,775	Restricted CDIs (representing 4,858,431 Shares) subject to escrow for 24 months from the commencement date of official quotation.
396,675	Restricted CDIs (representing 15,867 Shares) subject to escrow for 12 months from the date of issue, being 7 December 2017.
418,592	Unquoted Options over shares, exercisable at US\$22.72 with various expiry dates after the date of grant to be held in escrow for 24 months from the date of commencement of official quotation.
21,756	Unquoted Options over shares, exercisable at US\$2.20 with an expiry date after the date of grant to be held in escrow for 24 months from the date of commencement of official quotation.
11,028	Unquoted Options over shares, exercisable at US\$1.25 with an expiry date after the date of grant to be held in escrow for 24

⁺ See chapter 19 for defined terms.

	months from the date of commencement of official quotation.
76,175	Unquoted Options over shares, exercisable at US\$2.20 with various expiry dates after the date of grant
27,724	Unquoted Options over shares, exercisable at US\$1.25 with various expiry dates after the date of grant
121,621	Unquoted Options over shares, exercisable at USD\$23.85 expiring on 24 December 2027.
48,292	Unquoted Options over shares, exercisable at USD\$25.30 expiring on 29 January 2028.
85,000	Unquoted Options over shares, exercisable at USD\$21.56 expiring on 23 February 2028.
17,491	Unquoted Options over shares, exercisable at USD\$17.11 expiring on 23 April 2028.
24,060	Unquoted Options over shares, exercisable at USD\$17.05 expiring on 25 July 2028.
25,000	Unquoted Options over shares, exercisable at USD\$15.99 expiring on 9 September 2028.
10,136,669	Shares over common stock (unquoted).

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A

⁺ See chapter 19 for defined terms.

23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A
		1

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	- 1	one)
(a)		⁺ Securities described in Part 1 – Seeking quotation only in relation to the 212,050 CDIs being issued. Quotation is not being sought for the Shares and Options.
(b)		All other ⁺ securities
		Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional +securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of +securities for which +quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?	N/A	
	If the additional +securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)	N/A	
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	N/A	N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Stoll		
	Director		
Date:	September 11 2018	Print name:	Stephen Dash

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue		
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period		
"A"		

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	
Step 3: Calculate "C", the amount of place already been used	ement capacity under rule 7.1 that has
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	
• Under an exception in rule 7.2	
• Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	
Step 4: Subtract "C" from ["A" x "B"] capacity under rule 7.1	to calculate remaining placement
"A" x 0.15	
Note: number must be same as shown in Step 2	
Subtract "C"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2:

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Step 2: Calculate 10% of "A"	
"D"	0.10 Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount of p has already been used Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	lacement capacity under rule 7.1A that
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	
Subtract "E" Note: number must be same as shown in Step 3	0
Total ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.